Compare AIT & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIT | CYTK |
|---|---|---|
| Founded | 1923 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 10.7B |
| IPO Year | 1994 | 2004 |
| Metric | AIT | CYTK |
|---|---|---|
| Price | $338.26 | $78.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 19 |
| Target Price | ★ $317.50 | $89.26 |
| AVG Volume (30 Days) | 238.0K | ★ 1.8M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | ★ 8.20 | N/A |
| EPS | ★ 10.95 | N/A |
| Revenue | ★ $21,485,000.00 | $13,368,000.00 |
| Revenue This Year | $7.79 | $7.37 |
| Revenue Next Year | $5.45 | $310.19 |
| P/E Ratio | $31.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $238.34 | $35.22 |
| 52 Week High | $374.80 | $88.31 |
| Indicator | AIT | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 51.89 |
| Support Level | $331.42 | $78.27 |
| Resistance Level | $345.48 | $79.66 |
| Average True Range (ATR) | 7.85 | 2.07 |
| MACD | -2.67 | 0.36 |
| Stochastic Oscillator | 12.14 | 82.91 |
Applied Industrial Technologies Inc is a distributor of industrial products to the maintenance, repair, and operations market and the original equipment manufacturing industry. Further, the company provides engineering and design services for industrial and fluid power applications. The products include bearings, power transmission components, fluid power components and systems, industrial rubber products, linear motion components, safety products, oilfield supplies, and other industrial and maintenance supplies. The company's reportable segments are; Service Center Based Distribution which derives key revenue, and Engineered Solutions. Geographically, the company derives its key revenue from the United States and the rest from Canada and other countries.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.